Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
The Ava Protocol serves as the mainnet launch of EigenLayer AVS on Ethereum

The Ava Protocol serves as the mainnet launch of EigenLayer AVS on Ethereum

Bitget2024/07/16 14:17

The infrastructure based on intent, Ava Protocol, has launched its mainnet on Ethereum. As the EigenLayer AVS used for smart contract automation, it "enhances Web3 transaction efficiency, privacy and composability," said the team. This allows developers to integrate event-driven super transactions without custom code, simplifying complex chain operations and providing advanced features beyond the Ethereum Virtual Machine (EVM), supporting automated tasks such as payments and dynamic NFT minting.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "copper rush" cools off? LME sees the largest delivery in nearly four weeks, copper price retreats to $14,000

Copper prices have stabilized around $14,000 per ton after previously falling, as exchange-tracked warehouses have experienced a new round of inventory deliveries, indicating that the supply shortage has somewhat eased.

智通财经2026/09/15 04:01
The "copper rush" cools off? LME sees the largest delivery in nearly four weeks, copper price retreats to $14,000

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage